Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome

Background: Chimeric antigen receptor T-cell therapy (CAR T-cell therapy) is associated with potentially life-threatening toxicities, most commonly cytokine release syndrome (CRS) and immune-effector-cell-associated neurotoxicity syndrome (ICANS). These frequent adverse events are managed with the I...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Tim Lakomy, Dilara Akhoundova, Henning Nilius, Marie-Noëlle Kronig, Urban Novak, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2023-02-01
سلاسل:	Biomolecules
الموضوعات:	CAR T-cell therapy adverse events CRS neurotoxicity ICANS tocilizumab
الوصول للمادة أونلاين:	https://www.mdpi.com/2218-273X/13/2/382
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!